Purchase textbook

Chimeric Antigen Receptor T-Cell Therapies for Cancer,

Edition 1 A Practical Guide

Editors: Edited by Daniel W. Lee and Nirali N. Shah

Publication Date: 02 Dec 2019

0 Reviews

Conformance

PDF/UA-1
The publication was certified on 20250728
For queries regarding accessibility information, contact [email protected]

Ways Of Reading

This e-publication is accessible to the full extent that the file format and types of content allow, on a specific reading device, by default, without necessarily including any additions such as textual descriptions of images or enhanced navigation.

Navigation

The contents of the PDF have been tagged to permit access by assistive technologies as per PDF-UA-1 standard.
Page breaks included from the original print source

Additional Accessibility Information

The language of the text has been specified (e.g., via the HTML or XML lang attribute) to optimise text-to-speech (and other alternative renderings), both at the whole document level and, where appropriate, for individual words, phrases or passages in a different language.

Note

This product relies on 3rd party tooling which may impact the accessibility features visible in inspection copies. All accessibility features mentioned would be present in the purchased version of the title.

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area.

Key Features

Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care.
Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care.

Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon.

Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

About the author

Edited by Daniel W. Lee and Nirali N. Shah, Lasker Clinical Research Scholar, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, United States

Introduction
1. When to Refer a Patient for CAR-T Cell Therapy
2. Optimizing the Apheresis Product
3. CAR T Cells: Cell Processing Laboratory Considerations
4. Peri-CAR-T Cell Management
5. Management of Cytokine Release Syndrome
6. Special Considerations for ICU Management of Patients Receiving CAR Therapy
7. Neurotoxicities After CAR-T Cell Immunotherapy
8. Hematologic and Non-CRS Toxicities
9. Response Assessment and PosteCAR-T Cell Therapy Management
10. Relapse Management and Role for Consolidative Hematopoietic Stem Cell Transplantation Following CAR-T Cell Therapy
11. Promising Chimeric Antigen Receptors for Non-B Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas
12. CAR T Cell Therapy for CNS Malignancies
13. CAR 2.0: The Next Generation of Synthetic ReceptoreBased Cellular Therapy for Cancer

Chimeric Antigen Receptor T-Cell Therapies for Cancer,

Editors: Edited by Daniel W. Lee and Nirali N. Shah

Description

Key Features

About the author